Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma

Abstract

Objective: This study aimed to investigate the correlations of long non-coding RNA ANRIL (lncRNA ANRIL), microRNA (miR)-34a, miR-125a and miR-186 with disease risk, clinical features and prognosis of multiple myeloma (MM). Method: Totally, 87 MM patients and 30 controls were recruited. LncRNA ANRIL and its target miRNAs (miR-34a, miR-125a and miR-186) in bone marrow derived plasma cells were detected by RT-qPCR. Treatment response was assessed and survivals were calculated in MM patients. Results: LncRNA ANRIL expression was increased, while miR-34a, miR-125a and miR-186 expressions were reduced in MM patients compared with controls. Meanwhile, lncRNA ANRIL negatively correlated with miR-34a and miR-125a but not miR-186 in MM patients, while did not correlate with miR-34a, miR-125a or miR-186 in controls. In MM patients, lncRNA ANRIL high expression associated with higher beta-2-microglobulin (β2-MG) and more advanced international staging system (ISS) stage; miR-125a high expression associated with lower β2-MG, less advanced ISS stage and less t (14; 16) abnormality; miR186 high expression associated with increased albumin; while miR-34a did not associate with any clinical features. Furthermore, lncRNA ANRIL high expression associated with decreased complete response (CR), while miR-34a high and miR-125a high expression associated with increased CR and objective response rate. Additionally, lncRNA ANRIL high expression associated with shorter progression-free survival (PFS), while miR-34a high expression associated with prolonged overall survival (OS), and miR-125a high expression associated with longer PFS and OS. Conclusion: LncRNA ANRIL and its target miRNAs might serve as biomarkers for assisting with personalized treatment and prognosis improvement of MM.

LncRNA ANRIL promotes glucose metabolism and proliferation of colon cancer in a high-glucose environment and associated with worse outcome in diabetic colon cancer patients

“…There was a negative connection between ANRIL and miR-186-5p expression in this investigation. A subsequent research in multiple myeloma [32] con rmed these ndings.…”

Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma

“…Since ANRIL is unlikely to be the only lncRNA that contributes to chemosensitivity, subsequent animal studies are warranted to assess the effect of ANRIL in the osteosarcoma response to chemotherapy in vivo. Furthermore, the microRNAs that are negatively regulated by ANRIL (such as miR-34a, miR-125a, and miR-186) should be investigated, as should their putative role in bone remodeling and osteosarcoma onset [ 70 ]. Further studies would include the investigation of these targets in osteosarcoma models that are particularly related to chemosensitivity.…”

ANRIL regulates multiple molecules of pathogenetic significance in diabetic nephropathy

“…Hence ANRIL may be a target for future anti-inflammatory drugs [29]. In other system ANRIL has been demonstrated to work by regulating microRNAs [30]. As microRNA alterations happen frequently in most disease conditions including diabetic complications, possibility that ANRIL works through specific microRNA remains a possibility and need to be further investigated [17,18,31,32].…”